Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders

ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.

Saved in:
Bibliographic Details
Main Authors: Fonseca-Hial,Ana Marcela Rojas, Parisio,Katya, Oliveira,Jose Salvador Rodrigues
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2016
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-84842016000200099
record_format ojs
spelling oai:scielo:S1516-848420160002000992016-06-29Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disordersFonseca-Hial,Ana Marcela RojasParisio,KatyaOliveira,Jose Salvador Rodrigues Hematopoietic stem cell transplant Indolent lymphoproliferative disorder Reduced intensity conditioning Graft-versus-lymphoma Allogeneic ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.38 n.2 20162016-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099en10.1016/j.bjhh.2016.02.006
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Fonseca-Hial,Ana Marcela Rojas
Parisio,Katya
Oliveira,Jose Salvador Rodrigues
spellingShingle Fonseca-Hial,Ana Marcela Rojas
Parisio,Katya
Oliveira,Jose Salvador Rodrigues
Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
author_facet Fonseca-Hial,Ana Marcela Rojas
Parisio,Katya
Oliveira,Jose Salvador Rodrigues
author_sort Fonseca-Hial,Ana Marcela Rojas
title Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_short Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_full Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_fullStr Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_full_unstemmed Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_sort allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
description ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.
publisher Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publishDate 2016
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099
work_keys_str_mv AT fonsecahialanamarcelarojas allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders
AT parisiokatya allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders
AT oliveirajosesalvadorrodrigues allogeneichematopoieticstemcelltransplantationinpatientswithadvancedindolentlymphoproliferativedisorders
_version_ 1756423602696093696